Any current/future new fundraising through debt or equity?

No explicit mention of new fundraising through debt or equity was made in the Q4 FY'24 earnings call excerpts. The company has a gross debt of Rs. 990.6 crores and a net cash position of Rs. 667.7 crores as of March 31, 2024. CAPEX for FY'25 is budgeted at Rs. 700 crores, funded internally through cash flow, with no mention of external fundraising. The management indicated plans for in-licensing of products rather than big M&A, suggesting a conservative capital approach. No statements or guidance were provided indicating plans for raising new equity or debt financing in the near term.

Any current/future capex/capital investment/strategic investment?

Glenmark plans a consolidated capital investment (CAPEX) of Rs. 700 crores for FY'25. This CAPEX excludes GLS-related investments, which were part of prior years. The Rs.700 crores will be invested in: - Adding new production lines to support business growth, including capacity for products like RYALTRIS. - Potential in-licensing of additional products to expand the portfolio, rather than major M&A. There is significant front-ended CAPEX planned this year to prepare for stronger performance expected in FY'26. The Monroe facility's injectable line is expected to be commercialize

Future growth expectations in sales/revenue/volumes?

RYALTRIS is in the launch phase with expected peak sales of $200-$300 million over the next 3-5 years. Growth to be driven by expansions into major markets like Mexico, Brazil, and China starting FY'26. Significant market share gains anticipated in Europe, emerging markets, and the US (where growth from partners like Hikma is expected). European respiratory product launches and entry into new markets like the UK and South Africa also expected to fuel growth. Emerging markets remain key growth drivers alongside established markets. Plans to launch first generic Salmeterol + Fluticasone MDI in B

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark expects FY'25 to be a stable year with a revenue target of Rs. 13,500-13,750 crores and an EBITDA margin close to 19%. R&D spend is expected around 7%-7.5% of revenues, steady at about Rs. 1,000 crores. CAPEX guidance for FY'25 is about Rs. 700 crores, focused on additional lines and in-licensing products. FY'26 is anticipated to be a stronger growth year with significant topline growth expected, supported by launches (e.g., generic Flovent, RYALTRIS expansion). EPS and profitability are expected to improve from FY'26 onward, but detailed guidance will be shared at the upcoming Invest

Current/ Expected Orderbook/ Pending Orders?

The document does not explicitly mention a specific current or expected order book or pending orders for Glenmark Pharmaceuticals. However, it highlights growth prospects and product launches indicating a strong future sales pipeline, such as: - RYALTRIS launched in 34 markets with expected peak sales of $200-300 million over 3-5 years. - Generic Flovent filings with expected launch in FY'26; potential market size ~$400 million for one SKU and $1.6 billion collectively for related SKUs. The company targets consolidated revenues of Rs.135,000 to Rs.140,000 million for FY'25. Glenmark's pipe

Glenmark Pharma.Q4 FY24Pharmaceuticals & Biotechnology

Glenmark Pharma. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,331P/E: 21.5Market Cap: ₹67.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

RYALTRIS is in the launch phase with expected peak sales of $200-$300 million over the next 3-5 years.
Growth to be driven by expansions into major markets like Mexico, Brazil, and China starting FY'26.
Significant market share gains anticipated in Europe, emerging markets, and the US (where growth from partners like Hikma is expected).
European respiratory product launches and entry into new markets like the UK and South Africa also expected to fuel growth.
Emerging markets remain key growth drivers alongside established markets.
Plans to launch first generic Salmeterol + Fluticasone MDI in Brazil and generic Flovent in the US (FY'26), a $400+ million opportunity.
FY'26 flagged as a big year with substantial top line growth anticipated; additional capacity and CAPEX planned accordingly.
Overall, the company anticipates double-digit growth in sales driven by new product launches, market expansion, and increasing branded market contribution.

Margin guidance

Category 3

Glenmark expects FY'25 to be a stable year with a revenue target of Rs. 13,500-13,750 crores and an EBITDA margin close to 19%.
R&D spend is expected around 7%-7.5% of revenues, steady at about Rs. 1,000 crores.
CAPEX guidance for FY'25 is about Rs. 700 crores, focused on additional lines and in-licensing products.
FY'26 is anticipated to be a stronger growth year with significant topline growth expected, supported by launches (e.g., generic Flovent, RYALTRIS expansion).
EPS and profitability are expected to improve from FY'26 onward, but detailed guidance will be shared at the upcoming Investor Day.
EBITDA margin target for FY'25 is ~19%, with double-digit PAT margin aimed.
Growth drivers include launch expansion in emerging markets, ramp-up of RYALTRIS sales, and better US market performance through partners.

See what Glenmark Pharma. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of new fundraising through debt or equity was made in the Q4 FY'24 earnings call excerpts.
The company has a gross debt of Rs. 990.6 crores and a net cash position of Rs. 667.7 crores as of March 31, 2024.
CAPEX for FY'25 is budgeted at Rs. 700 crores, funded internally through cash flow, with no mention of external fundraising.
The management indicated plans for in-licensing of products rather than big M&A, suggesting a conservative capital approach.
No statements or guidance were provided indicating plans for raising new equity or debt financing in the near term.

Order book

The document does not explicitly mention a specific current or expected order book or pending orders for Glenmark Pharmaceuticals.
However, it highlights growth prospects and product launches indicating a strong future sales pipeline, such as:
- RYALTRIS launched in 34 markets with expected peak sales of $200-300 million over 3-5 years.
- Generic Flovent filings with expected launch in FY'26; potential market size ~$400 million for one SKU and $1.6 billion collectively for related SKUs.
The company targets consolidated revenues of Rs.135,000 to Rs.140,000 million for FY'25.
Glenmark's pipeline includes robust R&D focusing on oncology and innovative biologics, channelized through IGI.
There is no direct data on order backlog or pending orders, but strategic partnerships, launches, and R&D investments suggest an active pipeline feeding future orders.

See what Glenmark Pharma. management said on order book — free account, 30 seconds.

Capex plans

Yes

Glenmark plans a consolidated capital investment (CAPEX) of Rs. 700 crores for FY'25.
This CAPEX excludes GLS-related investments, which were part of prior years.
The Rs.700 crores will be invested in:
- Adding new production lines to support business growth, including capacity for products like RYALTRIS.
- Potential in-licensing of additional products to expand the portfolio, rather than major M&A.
There is significant front-ended CAPEX planned this year to prepare for stronger performance expected in FY'26.
The Monroe facility's injectable line is expected to be commercialized this year while other lines are impaired and likely scrapped.
No big mergers or acquisitions are planned, but strategic in-licensing is a key focus to supplement organic growth.

Track Glenmark Pharma. — get its next earnings analysis in your feed

How does Glenmark Pharma. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGlenmark Pharma.

Rev 3Mar 3

See where Glenmark Pharma. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Glenmark Pharma. rank in Pharmaceuticals & Biotechnology?

Compare Glenmark Pharma. against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Glenmark Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Glenmark Pharma. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Glenmark Pharma. rank in Pharmaceuticals & Biotechnology?

Continue your research

What Glenmark Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season